ClinicalTrials.Veeva

Menu
K

King Hussein Cancer Center | Office of Scientific Affairs and Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Hydroxychloroquine
Pertuzumab
Trastuzumab
Imatinib
Palbociclib
Azithromycin
Sirolimus
Prednisone
Giredestrant
Prednisolone

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 30 total trials
Status recently updated

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Enrolling
Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung ca...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Entrectinib
Drug: Crizotinib

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Ph...

Enrolling
Locally Advanced or Metastatic Breast Cancer
Drug: LHRH Agonist
Drug: Phesgo

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment i...

Active, not recruiting
Breast Cancer Stage II
Breast Cancer Stage III
Drug: doxorubicin/cyclophosphamide
Drug: Docetaxel / cyclophosphamide

The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a new standard for testing tumor progression compared wit...

Active, not recruiting
NSCLC
Drug: Gefitinib
Drug: Osimertinib

The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathol...

Active, not recruiting
Locally Advanced Rectal Cancer
Procedure: Total Mesorectal Excision
Drug: COMPOUND 2055269

Trial sponsors

K
E
Roche logo
H
Janssen (J&J Innovative Medicine) logo
Pfizer logo
S
University College London (UCL) logo
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems